10 Key ASCO 2014 Presentations in Lung CancerH. Jack West
Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference.
Adjuvant Endocrine Therapy For Postmenopausal Breast CancerEmad Shash
Questions Covered in the presentation:
• Should patients receive an AI or Tamoxifen?
• Should patients receive monotherapy (AI or Tamoxifen alone) or sequential
therapy using both?
• 5 vs 10 years of therapy?
• If More than 5 years of endocrine therapy, which class to be used
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
8. Aromatase inhibitor (AI)
• Non-steroidal
– block the peripheral conversion of androgens to
estrogens by inhibiting the heme porphyrin
portion of aromatase
– Letrozole (Femara®) & Anastrozle (Arimidex®)
• Steroidal
– binding irreversibly to the androgen binding site
– Exemestane (Aromasin®)
11. Postmenopausal adjuvant endocrine
therapy
勝
(DFS,OS Letrozole for 5 years
Tamoxifen for 5 years in LN+
MA.17
MA.17 Placebo for 5 years
N. Engl. J. Med. 349, 1793–1802 (2003)
Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
12. 勝 (DFS and
Postmenopausal adjuvant endocrine DMFS)
therapy
勝 (DFS and
OS)
Lancet 365, 1687–1717 (2005)
J. Clin. Oncol. 23, 5138–5147 (2005) Expert Rev. Anticancer Ther. 11(2), 277–286 (2011)
28. Reduction in percentage positive Ki67 Percentage of patient cases attaining a natural
from baseline to day 15 logarithm of percentage positive Ki67
of less than 1 at day 15
J Clin Oncol 2009;27:2630-7
31. Fulvestrant vs. Exemestane post non-
steroidal AI
P=0.6531
3.7 months
Duration 9.3 months
3.7 months
Duration 8.3 months
J Clin Oncol 2008;26:1664-70.
32. Everolimus + tamoxifen vs. tamoxifen
• Randomized phase 2 study
• 111 postmenopausal women
• ER-positive advanced breast cancer
• previously treated with an aromatase inhibitor
• PFS
– 8.6 months vs. 4.5 months, P = 0.002
• OS
– median not reached vs. 24.4 months, P = 0.01
33rd Annual San Antonio Breast Cancer
Symposium, San Antonio, TX,
December 8–12, 2010.
33.
34. Everolimus in Postmenopausal
Hormone-Receptor–Positive Advanced Breast Cancer
Study design
• International
• Double-blind randomized (2:1)
• Phase 3 study
• oral everolimus (10 mg qd) or matching
placebo in conjunction with exemestane (25
mg qd)
N Engl J Med 2011 Dec 7.
35. Everolimus in Postmenopausal
Hormone-Receptor–Positive Advanced Breast Cancer
Patients
• postmenopausal women
• ER-positive
• nonamplified HER2
• refractory to previous letrozole or anastrozole
– recurrence during or within 12 months after the
end of adjuvant treatment
– progression during or within 1 month after the
end of treatment for advanced disease
N Engl J Med 2011 Dec 7.
36. Everolimus in Postmenopausal
Hormone-Receptor–Positive Advanced Breast Cancer
End point
• Primary: PFS
• Secondary
– overall survival
– overall response rate
– clinical benefit rate
– time to deterioration of ECOG performance status
– safety
– Quality of life
• the European Organization for Research and Treatment of
Cancer quality-of life core questionnaire (QLQ-C30)
• the breast cancer module (QLQ-BR23)
N Engl J Med 2011 Dec 7.
41. Everolimus in Postmenopausal
Hormone-Receptor–Positive Advanced Breast Cancer
Safety
• Serious adverse events
– combination-therapy vs. exemestane-alone
– 23% (11% ) vs. 12% (1% )
• discontinue everolimus
– adverse events
• 19% vs. 4%
– withdrawal of consent
• 5% vs. 2%
• discontinue exemestane
– adverse events
• 7% vs. 3%
– withdrawal of consent
• 7% vs. 2%
N Engl J Med 2011 Dec 7.
42. 6.9 vs. 2.8 ms
HR : 0.43
95% CI : 0.35-0.54
P<0.001
10.6 vs. 4.1 ms
HR : 0.36
95% CI : 0.27-0.47
P<0.001
N Engl J Med 2011 Dec 7.
47. Everolimus in Postmenopausal
Hormone-Receptor–Positive Advanced Breast Cancer
Overall survival
• immature at the time of the interim analysis
– combination-therapy vs. exemestane-alone
– 10.7% vs. 13%
N Engl J Med 2011 Dec 7.
48. Discussion
• Adverse events of everolimus
– stomatitis, fatigue, asthenia, diarrhea, cough, pyre
xia, and hyperglycemia
• Higher percentage of patients discontinued
everolimus because of a lack of tolerability
N Engl J Med 2011 Dec 7.
49. Summary
• Addition of everolimus to endocrine therapy
results in an improved clinical outcome
• Benefit should be weighed against the side
effects observed with everolimus
• Potential of everolimus to benefit patient
survival is not yet known